Drug intelligence / Profile preview

GSK232802

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK232802 is a small molecule drug developed by GSK (GlaxoSmithKline) as a non-hormonal treatment for vasomotor symptoms, specifically hot flashes and flushes in postmenopausal women. It acts as a selective modulator of the estrogen receptor alpha (ERα), aiming to regulate gene expression associated with menopausal symptoms without the use of traditional hormone therapy. The compound was investigated in Phase 2 clinical trials for its efficacy and safety in reducing the frequency and severity of hot flashes related to menopause[1][3][7][9].

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on GSK232802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK232802.

Explore the full profile